SCHEMBL7056743

SCHEMBL7056743

NC(=O)c1cc2c(-c3ccccc3)cncc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 12/20 1.00
PIM1 P11309 11/20 1.00
GSK3B P49841 11/20 1.00
DYRK1A Q13627 11/20 1.00
CDK2 P24941 10/20 1.00
CSNK1D P48730 10/20 1.00
CDK5 Q00535 9/20 1.00
CHEK2 O96017 9/20 1.00
MAPK9 P45984 9/20 1.00
CDK1 P06493 9/20 1.00
KDR P35968 9/20 1.00
AURKB Q96GD4 9/20 1.00
DAPK3 O43293 8/20 1.00
LIMK1 P53667 8/20 1.00
PLK4 O00444 8/20 1.00
AURKA O14965 8/20 1.00
RPS6KA3 P51812 7/20 1.00
CSNK2A1 P68400 7/20 1.00
PRKACA P17612 7/20 1.00
SGK2 Q9HBY8 7/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19769129 0.92 MAP3K8 (1.00) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL19780834 0.89 PIM1 (0.80) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL19769161 0.89 PIM1 (0.79) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL7619323 0.88 GSK3A (1.00) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL5550778 0.88 PIM1 (0.78) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL5555786 0.87 PIM1 (0.78) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL5550289 0.87 MAP3K8 (0.77) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL7055360 0.86 PIM1 (0.76) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL7055380 0.86 PIM1 (1.00) GSK3APIM1GSK3BDYRK1ACDK2
SCHEMBL7050653 0.86 GSK3A (1.00) GSK3APIM1GSK3BDYRK1ACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 US claimed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 EP claimed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 US claimed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 EP claimed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 WO claimed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 WO claimed
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 US disclosed
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds STEWART ANDREW O (US) 2003-11-27 US disclosed
US-6579882-B2 Thieno(2,3-d)pyrimidine derivatives ABBOTT LABORATORIES 2003-06-17 US disclosed
EP-1181296-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2002-02-27 EP disclosed
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ABBVIE INC. 2001-09-06 US disclosed
US-6232320-B1 THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES ABBOTT LABORATORIES 2001-05-15 US disclosed
EP-1090009-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2001-04-11 EP disclosed
WO-2000075145-A1 CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 2000-12-14 WO disclosed
WO-1999062908-A2 CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS ABBOTT LABORATORIES (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020030-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM GSK3A 3245/4885PIM1 2261/4885GSK3B 3044/4885
US-20030220365-A1 Cell adhesion-inhibiting antiinflammatory compounds ICAM1, VCAM1, EPCAM GSK3A 3245/4885PIM1 2261/4885GSK3B 3044/4885
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION CD4, CCR5, MMP8 GSK3A 1892/4885PIM1 1098/4885GSK3B 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.